Stockrabit · Analysts
Questions across 7 calls

Tarang Agrawal

Old Bridge

Aditya Birla Real Estate Limited

Aditya Birla Real Estate Limited CC-Feb26.pdf · 2026-01-29
Three questions from me. If I look at your GDV of INR70,000 crores, for your ongoing projects, what is the margin that you're working with? And for your upcoming projects, how would the margin profile work? And how much cash has already been invested between land approvals, designs and all the other activities around them?
But given that you have some projects which are yet to be launched, while I understand that the overall business is working with a negative working capital, it's really specifically for those INR44,000 crores worth of launches between the entire background work, how much would have been invested till date?

Gland Pharma Limited

Gland Pharma Limited CC-Feb26.pdf · 2026-01-28
Hi, I have two questions. One, if you could give us a sense on how the Cenexi trajectory should play out going forward from here on? And second, in your initial address, you did call out about investing INR2,000 crores. If you could give more color in terms of what is the time line within which you're looking at investing at, the approval time lines and kind of asset t urns that you would look out of investments given that it's going to be a mix of both volume as well as value?
Just a follow-up on this. I mean, what is driving this kind of confidence? I mean from the point of view of customers, you did call out demand, you did call out India being an innovation hub. So if you could just elaborate in terms of the structure of the industry, because there's a sizable portion now from the point of view of where your gross block is today and the kind of investment that you're committing?

UPL Limited

UPL Limited CC-Sep25.pdf · 2025-11-06
Congrats on a strong set of numbers. I would just like to take this forum to basically call out that considering how UPL was one of the first ones to call out the stress in the environment, taking the write-offs, I think life seems to have come to full circle, especially given the context in which some of the global peers have reported. Also sincerely appreciate the improvement in the financial reporting quality and the earnings quality. We really hope this momentum both on reporting as well as business, continues. Now coming on to the questions, I actually have three . Firstly, on UPL Corp, what should be the steady-state contribution margins for this business? And where I'm coming from is I'm not trying to look at it on a quarterly basis, but say, what is the target that you are hoping to achieve, say, in FY27, maybe '28? And secondly, what's the share of D&S business? I think these disclosures used to be given out. I think for the last two quarters, these disclosures are missing. So, it will help if you could incorporate it going forward. And the rest are relating to Bikash and SUPERFORM.
Bikash, how confident are you in continuing to yield the supply payment terms that you're currently yielding?
UPL Limited CC-Jun25.pdf · 2025-08-01
Hi. Good evening. Quite a few questions. First on the financials, Bikash, we have been consistently seeing a reduction in debt, but it is not translating into reduction in interest cost. So, I understand there are multiple factors. Historically, you used to give us a more granular disclosure. So, if you could please comment, how should we see the interest cost number moving from here on? And a follow -up on that, if you c ould just give us some sense on how is your costing when it comes to your payables versus your cost of factoring?
So, Bikash, I mean because we do not have these disclosures, right, it's difficult for us to probably evaluate what portion of interest cost is on borrowings, and what portion is otherwise. So , I would request you to properly disclose this going forward. That will be very helpful. Second, the number was ballpark of about Rs. 1,000 crores, okay? $74 million translates to roughly Rs. 650 crores. So, what is this balance Rs. 350 crores?

Deepak Fertilizers and Petrochemicals Corporation Limited

Deepak Fertilizers and Petrochemicals Corporation Limited CC-Mar25.pdf · 2025-05-23
Just a couple of questions, rather bookkeeping. You said for TAN, is the license capacity 587 Kt or 630 Kt? Subhash Anand: It’s 587. TAN capacity you are taking.
Right. Okay. Got it. Second, how big is LDAN for you? And what is the significance of the B2C metric that you laid out in the presentation? Subhash Anand: Okay. No, in fact, the LDAN is basically a product, which gets used as an explosive in the mines or in infrastructure. So, we used to sell most of our product as a B2B segment of late. As a part of our TCO, we started working with end consumers, which is various mines and infra and started working with them to supply LDAN directly to them. And that ’s how our downstream business or a B2C journey in TAN is expanding. And now we have reached to a level where our 18% of the share comes from our sale to B2C segments.

Granules India Limited

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited CC-Mar24.pdf · 2024-05-07
Hi, congrats for a really strong set of numbers. Just a couple of questions. Capital expenditures stepped up quite a lot in both FY23 and FY24. If I look at 2024 alone, its roughly Rs. 2,700 crores of capex. So if you could just give us a sense, in terms of a broad set of baskets, where this Rs. 2,700 crores would have been deployed. So, that is number one. Second, till date if between P&L and balance sheet, if you could give us a sense on what your cumulative investments in biosimilars has been and third , just a general sense on where your overall biosimilar business is at?
Yeah, this is alright. So, when you say expansion, these are broad buckets. I mean it is going into API, injectable, biologics and Aurigene, right?